Business
Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer
WALTHAM, Mass., June 13, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"WALTHAM, Mass., June 13, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (\"Syndax,\" the \"Company\" or \"we\") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Keith A. Goldan to the role of Chief Financial Officer, effective immediately. Mr. Goldan, who brings to Syndax nearly thirty years of leadership and operational experience at several pharmaceutical, biotechnology, and medical technology companies, most recently served as Chief Financial Officer at Optinose®, where he helped build the infrastructure to support the launch of XHANCE® (fluticasone propionate) in the United States. As Chief Financial Officer at Syndax, Mr. Goldan will oversee corporate finance and accounting, financial strategy, and investor relations.\n\"It is a pleasure to welcome Keith to the Syndax team at this exciting time for the Company,\" said Michael A. Metzger, Chief Executive Officer. \"Keith's experience as an accomplished CFO with deep financial and operational expertise along with a solid track record of building and financing successful biopharmaceutical companies will be invaluable as we scale to a fully-integrated commercial stage company.\"\n\"I look forward to joining the highly motivated team at Syndax and contributing to future progress,\" said Mr. Goldan. \"Syndax is well positioned to achieve its strategic goals with multiple pivotal readouts next year for revumenib and axatilimab, both of which have significant commercial potential as first- and best-in-class therapies in areas of clear unmet need, and meaningful expansion opportunities into earlier lines of therapy and additional indications.\"\nMr. Goldan has served as Chief Financial Officer of numerous private and public biopharmaceutical companies from early stage through commercial stage, including Optinose, Fibrocell, NuPathe, PuriCore plc, and Biosyn. During his career, he led the successful execution of multiple initial public offerings and follow-on equity, rights, private placement, and debt offerings, as well as several merger and acquisition transactions. Mr. Goldan received a B.S. in Finance from the Robert H. Smith School of Business at the University of Maryland and an M.B.A. from the Wharton School at the University of Pennsylvania.\nSyndax also announced today the ...